Assessment of cell-cycle arrest biomarkers to predict early and delayed acute kidney injury

Disease Markers

Volumn 2015, Issue , 2015, Pages

  Bell, Max ^a   Larsson, Anders ^b   Venge, Per ^b   Bellomo, Rinaldo ^c,d   Mårtensson, Johan ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c AUSTIN HOSPITAL   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CREATININE; CYSTATIN C; INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 7; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; SOMATOMEDIN BINDING PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG; ACUTE PHASE PROTEIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-RELATED PROTEIN 1; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; APACHE; ARTICLE; CARDIOVASCULAR DISEASE; CELL CYCLE ARREST; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEPSIS; URINALYSIS; CASE CONTROL STUDY; CELL CYCLE CHECKPOINT; MIDDLE AGED; URINE;

ACUTE KIDNEY INJURY; ACUTE-PHASE PROTEINS; ADULT; AGED; BIOMARKERS; CASE-CONTROL STUDIES; CELL CYCLE CHECKPOINTS; CYSTATIN C; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; LIPOCALINS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84926483489     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2015/158658     Document Type: Article

References (27)

1. T. Z. Ali, I. Khan, W. Simpson et al., "Incidence and outcomes in acute kidney injury: a comprehensive population-based study", Journal of the American Society of Nephrology, Vol. 18, no. 4, pp. 1292-1298, 2007.
2. M. Bell, F. Granath, S. Schön, A. Ekbom, and C.-R. Martling, "Continuous renal replacement therapy is associated with less chronic renal failure than intermittent haemodialysis after acute renal failure", Intensive Care Medicine, Vol. 33, no. 5, pp. 773-780, 2007.
3. S. G. Coca, S. Singanamala, and C. R. Parikh, "Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis", Kidney International, Vol. 81, no. 5, pp. 442-448, 2012.
4. S. Uchino, J. A. Kellum, R. Bellomo et al., "Acute renal failure in critically ill patients: a multinational, multicenter study", The Journal of the American Medical Association, Vol. 294, no. 7, pp. 813-818, 2005.
5. S. G. Coca, R. Yalavarthy, J. Concato, and C. R. Parikh, "Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review", Kidney International, Vol. 73, no. 9, pp. 1008-1016, 2008.
6. K. Kashani, A. Al-Khafaji, T. Ardiles et al., "Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury", Critical Care, Vol. 17, article R25, 2013.
7. J. Mårtensson, C.-R. Martling, and M. Bell, "Novel biomarkers of acute kidney injury and failure: clinical applicability", British Journal of Anaesthesia, Vol. 109, no. 6, pp. 843-850, 2012.
8. J. Mishra, C. Dent, R. Tarabishi et al., "Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery", The Lancet, Vol. 365, no. 9466, pp. 1231-1238, 2005.
9. J. Mårtensson and R. Bellomo, "The rise and fall of NGAL in acute kidney injury", Blood Purification, Vol. 37, no. 4, pp. 304-310, 2014.
10. A. Bihorac, L. S. Chawla, A. D. Shaw et al., "Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication", The American Journal of Respiratory and Critical Care Medicine, Vol. 189, no. 8, pp. 932-939, 2014.
11. M. Meersch, C. Schmidt, H. van Aken et al., "Urinary TIMP-2 and IGFBP7 as early biomarkers of acute kidney injury and renal recovery following cardiac surgery", PLoS ONE, Vol. 9, no. 3, Article ID e93460, 2014.
12. F. Aregger, D. E. Uehlinger, J. Witowski et al., "Identification of IGFBP-7 by urinary proteomics as a novel prognostic marker in early acute kidney injury", Kidney International, Vol. 85, no. 4, pp. 909-919, 2014.
13. J. A. Kellum, N. Lameire, P. Aspelin et al., "Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part 1)", Critical Care, Vol. 17, no. 1, article 204, 2013.
14. G. R. Bernard, J.-L. Vincent, P.-F. Laterre et al., "Eficacy and safety of recombinant human activated protein C for severe sepsis", The New England Journal of Medicine, Vol. 344, no. 10, pp. 699-709, 2001.
15. R. C. Bone, R. A. Balk, F. B. Cerra et al., "Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine", Chest, Vol. 101, no. 6, pp. 1644-1655, 1992.
16. L. Cai, J. Borowiec, S. Xu, W. Han, and P. Venge, "Assays of urine levels of HNL/NGAL in patients undergoing cardiac surgery and the impact of antibody configuration on their clinical performances", Clinica Chimica Acta, Vol. 403, no. 1-2, pp. 121-125, 2009.
17. S. Y. Xu, M. Carlson, A. Engstrom, R. Garcia, C. G. B. Peterson, and P. Venge, "Purification and characterization of a human neutrophil lipocalin (HNL) from the secondary granules of human neutrophils", Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 54, no. 5, pp. 365-376, 1994.
18. H. Gomez, C. Ince, D. de Backer et al., "A unified theory of sepsis-induced acute kidney injury: Inflammation, micro-circulatory dysfunction, bioenergetics, and the tubular cell adaptation to injury", Shock, Vol. 41, no. 1, pp. 3-11, 2014.
19. Q.-H. Yang, D.-W. Liu, Y. Long, H.-Z. Liu, W.-Z. Chai, and X.-T. Wang, "Acute renal failure during sepsis: potential role of cell cycle regulation", The Journal of Infection, Vol. 58, no. 6, pp. 459-464, 2009.
20. R. Witzgall, D. Brown, C. Schwarz, and J. V. Bonventre, "Localization of proliferating cell nuclear antigen, vimentin, c-Fos, and clusterin in the postischemic kidney. Evidence for a heterogenous genetic response among nephron segments, and a large pool of mitotically active and dedifferentiated cells", The Journal of Clinical Investigation, Vol. 93, no. 5, pp. 2175-2188, 1994.
21. J. Mårtensson, M. Bell, A. Oldner, S. Xu, P. Venge, and C.-R. Martling, "Neutrophil gelatinase-associated lipocalin in adult septic patients with and without acute kidney injury", Intensive Care Medicine, Vol. 36, no. 8, pp. 1333-1340, 2010.
22. J. Mårtensson, M. Bell, S. Xu et al., "Association of plasma neutrophil gelatinase-associated lipocalin (NGAL) with sepsis and acute kidney dysfunction", Biomarkers, Vol. 18, no. 4, pp. 349-356, 2013.
23. J. Mårtensson, N. J. Glassford, S. Jones et al., "Urinary neu-trophil gelatinase-associated lipocalin to hepcidin ratio as a biomarker of acute kidney injury in intensive care unit patients", Submitted to Minerva Anestesiologica.
24. T. L. Nickolas, M. J. O'Rourke, J. Yang et al., "Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury", Annals of Internal Medicine, Vol. 148, no. 11, pp. 810-819, 2008.
25. M. Nejat, J. W. Pickering, R. J. Walker et al., "Urinary cystatin C is diagnostic of acute kidney injury and sepsis, and predicts mortality in the intensive care unit", Critical Care, Vol. 14, no. 3, article R85, 2010.
26. J. Mårtensson, C.-R. Martling, A. Oldner, and M. Bell, "Impact of sepsis on levels of plasma cystatin C in AKI and non-AKI patients", Nephrology Dialysis Transplantation, Vol. 27, no. 2, pp. 576-581, 2012.
27. A. Haase-Fielitz, M. Haase, and R. Bellomo, "Instability of urinary NGAL during long-term storage", American Journal of Kidney Diseases, Vol. 53, no. 3, pp. 564-565, 2009.